Wave Life Sciences (NASDAQ:WVE - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.34, Zacks reports. The company had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.
Wave Life Sciences Stock Performance
Shares of NASDAQ WVE traded down $0.78 during mid-day trading on Friday, hitting $9.40. The stock had a trading volume of 1,764,710 shares, compared to its average volume of 939,773. The firm has a market cap of $1.43 billion, a PE ratio of -8.47 and a beta of -1.09. The company has a 50 day moving average of $11.51 and a two-hundred day moving average of $11.18. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74.
Wall Street Analysts Forecast Growth
WVE has been the topic of a number of recent research reports. Jefferies Financial Group started coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective on the stock. Truist Financial raised their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, November 12th. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday. Mizuho increased their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Finally, StockNews.com raised shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.60.
View Our Latest Analysis on WVE
About Wave Life Sciences
(
Get Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Featured Stories
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
